Advanced search
Publication Cover
Emerging Microbes & Infections Volume 5, 2016 - Issue 1
Submit an article Journal homepage
1,281
Views
26
CrossRef citations to date
0
Altmetric
Original Articles

Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials

Qiaoling Ruan These authors contribute equally to the article.;Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Qihui Liu These authors contribute equally to the article.;Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Feng SunDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Lingyun ShaoDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Jialin JinDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Shenglei YuDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Jingwen AiDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
,
Bingyan ZhangDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, China
&
Wenhong ZhangDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai200040, ChinaCorrespondence[email protected]
 show all
Pages 1-8 | Received 30 Aug 2015, Accepted 16 Nov 2015, Published online: 25 Jan 2019

  • World Health Organization.Global tuberculosis report 2014. Geneva: WHO, 2015.Available at http://www.who.int/tb/publications/global_report/archive/en/ accessed 31 August 2015).
  • MaZ,LienhardtC,McIlleronH,NunnAJ,WangX.Global tuberculosis drug development pipeline: the need and the reality.Lancet2010; 375:2100–2109.
  • GinsbergAM.Tuberculosis drug development: progress, challenges, and the road ahead.Tuberculosis (Edinb)2010; 90:162–167.
  • GospodarevskayaE,TullochO,BungaCet al.Patient costs during tuberculosis treatment in Bangladesh and Tanzania: the potential of shorter regimens.Int J Tuberc Lung Dis2014; 18:810–817.
  • GillespieSH,BillingtonO.Activity of moxifloxacin against mycobacteria.J Antimicrob Chemother1999; 44:393–395.
  • HuY,CoatesAR,MitchisonDA.Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.Antimicrob Agents Chemother2003; 47:653–657.
  • JiBH,LounisN,MasloC,Truffot-PernotC,BonnafousP,GrossetJ.In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.Antimicrob Agents Chemother1998; 42:2066–2069.
  • RodriguezJC,RuizM,LopezM,RoyoG.In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.Int J Antimicrob Agents2002; 20:464–467.
  • SulochanaS,RahmanF,ParamasivanCN.In vitro activity of Fluoroquinolones against Mycobacterium tuberculosis.J of Chemother2005; 17:169–173.
  • MiyazakiE,MiyazakiM,ChenJM,ChaissonRE,BishaiWR.Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis.Antimicrob Agents Chemother1999; 43:85–89.
  • NuermbergerEL,YoshimatsuT,TyagiSet al.Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.Am J Respir Crit Care Med2004; 169:421–426.
  • NuermbergerEL,YoshimatsuT,TyagiSet al.Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.Am J Respir Crit Care Med2004; 170:1131–1134.
  • GoslingRD,UisoLO,SamNEet al.The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.Am J Respir Crit Care Med2003; 168:1342–1345.
  • JohnsonJL,HadadDJ,BoomWHet al.Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.Int J Tuberc Lung Dis2006; 10:605–612.
  • PletzMW,De RouxA,RothA,NeumannKH,MauchH,LodeH.Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.Antimicrob Agents Chemother2004; 48:780–782.
  • WangJY,WangJT,TsaiTHet al.Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis.Int J Tuberc Lung Dis2010; 14:65–71.
  • ZiganshinaLE,TitarenkoAF,DaviesGR.Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).Cochrane Database Syst Rev2013; 6:Cd004795.
  • RubinsteinE,KeynanY.Quinolones for mycobacterial infections.Int J Antimicrob Agents2013; 42:1–4.
  • ChenZ,LiangJQ,WangJH,FengSS,ZhangGY.Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: a meta-analysis.Tuberculosis (Edinb)2015; 95:490–496.
  • GillespieSH,CrookAM,McHughTDet al.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.N Engl J Med2014; 371:1577–1587.
  • JindaniA,HarrisonTS,NunnAJet al.High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.N Engl J Med2014; 371:1599–1608.
  • MerleCS,FieldingK,SowOBet al.A four-month gatifloxacin-containing regimen for treating tuberculosis.N Engl J Med2014; 371:1588–1598.
  • MoherD,LiberatiA,TetzlaffJ,AltmanDG,Prisma Group.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Ann Intern Med2009; 151:264–269, W64.
  • HigginsJP,AltmanDG,GotzschePCet al.The cochrane collaboration's tool for assessing risk of bias in randomised trials.BMJ2011; 343:d5928.
  • HigginsJP,ThompsonSG,DeeksJJ,AltmanDG.Measuring inconsistency in meta-analyses.BMJ2003; 327:557–560.
  • BurmanWJ,GoldbergS,JohnsonJLet al.Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.Am J Respir Crit Care Med2006; 174:331–338.
  • RustomjeeR,LienhardtC,KanyokTet al.A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.Int J Tuberc Lung Dis2008; 12:128–138.
  • CondeMB,EfronA,LoredoCet al.Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.Lancet2009; 373:1183–1189.
  • DormanSE,JohnsonJL,GoldbergSet al.Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.Am J Respir Crit Care Med2009; 180:273–280.
  • JawaharMS,BanurekhaVV,ParamasivanCNet al.Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.PLoS One2013; 8:e67030.
  • VelayuthamBV,AllaudeenIS,SivaramakrishnanGNet al.Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.Clin Infect Dis2014; 59:E142–E149.
  • WallisRS,WangC,MeyerD,ThomasN.Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.PLoS One2013; 8:e71116.
  • WallisRS,PeppardT,HermannD.Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update.PLoS One2015; 10:e0125403.
  • MohrJF,McKinnonPS,PeymannPJ,KentonI,SeptimusE,OkhuysenPC.A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.Pharmacotherapy2005; 25:1303–1309.
  • GrosjeanP,UrienS.Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.J Clin Pharmacol2012; 52:329–338.
  • CamineroJA,SotgiuG,ZumlaA,MiglioriGB.Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.Lancet Infect Dis2010; 10:621–629.
  • FalzonD,JaramilloE,SchunemannHJet al.WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.Eur Respir J2011; 38:516–528.
  • ZhaoY,XuS,WangLet al.National survey of drug-resistant tuberculosis in China.N Engl J Med2012; 366:2161–2170.
  • AgrawalD,UdwadiaZF,RodriguezC,MehtaA.Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India.Int J Tuberc Lung Dis2009; 13:79–83.
  • GrimaldoER,TupasiTE,RiveraABet al.Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines.Int J Tuberc Lung Dis2001; 5:546–550.
  • MiglioriGB,LangendamMW,D'AmbrosioLet al.Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.Eur Respir J2012; 40:814–822.
  • DevasiaRA,BlackmanA,GebretsadikTet al.Fluoroquinolone resistance in Mycobacterium tuberculosis the effect of duration and timing of fluoroquinolone exposure.Am J Respir Crit Care Med2009; 180:365–370.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.